Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[123I]-CNS 1261 is a radiolabeled ligand used as a SPECT (Single Photon Emission Computed Tomography) imaging agent for the NMDA (N-methyl-D-aspartate) receptor, specifically binding to the MK801 intrachannel site. It is primarily utilized in research settings to study glutamatergic neurotransmission and NMDA receptor function in the human brain. The tracer allows for non-invasive quantification of NMDA receptor availability and has been investigated in neuropsychiatric disorders such as schizophrenia. Studies have shown that global binding of [123I]-CNS 1261 can be altered by antipsychotic treatment, indicating its potential utility in monitoring disease state or drug effects on glutamatergic systems[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [123I]-CNS 1261.